The Food and Drug Administration yesterday revised its emergency use authorization for the Johnson & Johnson COVID-19 vaccine to limit its use to individuals 18 and older for whom the other authorized or approved vaccines are not accessible or clinically appropriate, or who choose to receive it because they would otherwise not receive a vaccine.

“After conducting an updated analysis, evaluation and investigation of reported cases, the FDA has determined that the risk of thrombosis with thrombocytopenia syndrome (TTS), a syndrome of rare and potentially life-threatening blood clots in combination with low levels of blood platelets with onset of symptoms approximately one to two weeks following administration of the Janssen COVID-19 Vaccine, warrants limiting the authorized use of the vaccine,” the agency said.

For more information, see the fact sheet for health care providers administering the vaccine.

Related News Articles

Headline
The Centers for Disease Control and Prevention yesterday recommended children age 5-11 receive a booster dose five months after completing the Pfizer COVID-19…
Headline
U.S. residents can order online eight more free at-home tests for COVID-19, the White House announced yesterday. People who have difficulty accessing the…
Headline
The Food and Drug Administration today authorized a single Pfizer COVID-19 booster dose for children aged 5-11 who completed the Pfizer vaccine primary series…
Headline
The Food and Drug Administration yesterday approved using Olumiant (baricitinib) to treat COVID-19 in hospitalized adults requiring supplemental oxygen,…
Headline
The Food and Drug Administration last week extended to 24 months the shelf life for certain lots of refrigerated bamlanivimab. The combination monoclonal…
Headline
The Centers for Medicare & Medicaid Services Friday released updated guidance on COVID-19 vaccination coverage and reimbursement to help Medicaid, Children…